Join
Live feed
·
PRReleasevia Quantisnow
Cue Biopharma Inc. logo

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

ByQuantisnow·Wall Street's wire, on your screen.
CUE· Cue Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CUE (Cue Biopharma Inc.) and more on Quantisnow.